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Background: Fabry disease is an inborn lysosomal storage disorder which is associated with small fiber neuropathy.
We set out to investigate small fiber conduction in Fabry patients using pain-related evoked potentials (PREP).
Methods: In this case–control study we prospectively studied 76 consecutive Fabry patients for electrical small fiber
conduction in correlation with small fiber function and morphology. Data were compared with healthy controls
using non-parametric statistical tests. All patients underwent neurological examination and were investigated with
pain and depression questionnaires. Small fiber function (quantitative sensory testing, QST), morphology
(skin punch biopsy), and electrical conduction (PREP) were assessed and correlated. Patients were stratified for
gender and disease severity as reflected by renal function.
Results: All Fabry patients (31 men, 45 women) had small fiber neuropathy. Men with Fabry disease showed
impaired cold (p < 0.01) and warm perception (p < 0.05), while women did not differ from controls. Intraepidermal
nerve fiber density (IENFD) was reduced at the lower leg (p < 0.001) and the back (p < 0.05) mainly of men with
impaired renal function. When investigating A-delta fiber conduction with PREP, men but not women with Fabry
disease had lower amplitudes upon stimulation at face (p < 0.01), hands (p < 0.05), and feet (p < 0.01) compared to
controls. PREP amplitudes further decreased with advance in disease severity. PREP amplitudes and warm (p < 0.05)
and cold detection thresholds (p < 0.01) at the feet correlated positively in male patients.
Conclusion: Small fiber conduction is impaired in men with Fabry disease and worsens with advanced disease
severity. PREP are well-suited to measure A-delta fiber conduction.
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Fabry disease (FD) is an inborn lysosomal storage dis-
order with X-linked inheritance. Mutations in the gene
encoding the enzyme α-galactosidase A (α-GAL) lead to
a reduction or a complete loss of function of this key en-
zyme in cleavage of glycoconjugates. The consequence is
the accumulation of globotriaosylceramide (Gb3) in tis-
sues including kidneys, heart, and the nervous system
[1]. FD mostly affects the peripheral nervous system in* Correspondence: ueceyler_n@klinik.uni-wuerzburg.de
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reproduction in any medium, provided the orterms of small fiber neuropathy [2-5] with the main clin-
ical feature of burning pain at palms and soles upon ex-
ertion, fever or during hot temperatures [6].
A-delta and C-fiber function can be assessed by neuro-
logical examination and quantitative sensory testing
(QST). Both methods require high patient cooperation.
For a more objective assessment of pathways fed by A-
delta and C-fibers, specific stimulation and recording
techniques are needed. Besides laser and heat stimuli,
electrical current using special concentric electrodes [7]
is suitable to stimulate A-delta fibers. This type of evoked
potentials, which has been named “pain-related evoked
potentials” (PREP), is an easily applicable new tool for
objective small fiber diagnostics [8].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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delta fiber conduction with function and morphology. We
hypothesized that small fiber neuropathy in FD should be
associated with changes in A-delta pathways that are de-
tectable by PREP recordings and asked whether these
changes are associated with disease severity.
Methods
Subjects
We included 76 consecutive Fabry patients in this mono-
center case–control study (median age 43 years, range
16–73) in whom the diagnosis of FD was confirmed by
measurement of α-GAL activity in leucocytes (www.meta-
bolic-genetic-disease.gmxhome.de;Munich, Germany) and
genetically ascertained. The patients were prospectively
recruited (2009–2011) through the Wurzburg Fabry Cen-
ter for Interdisciplinary Therapy (FAZIT), University of
Wurzburg. FAZIT is a tertiary referral center where pa-
tients are seen from all over Germany to confirm the diag-
nosis and to initiate treatment. The cohort included 31
men (median age 39 years, 16–62) and 45 women (median
age 43 years, 18–73). Thirty-four patients (24 men, 10
women) were on enzyme replacement treatment (ERT; bi-
weekly infusions of agalsidase beta [1 mg/kg body weight]
in 29 patients and of agalsidase alpha [0.2 mg/kg body
weight] in 5 patients). The median time on ERT at study
enrolment was 4.7 years (range 0.1-9.3 years). QST and
skin punch biopsy data of 66 subjects from our patient co-
hort were part of a data set published earlier [5].
We compared our data with data of age- and gender-
matched healthy controls as detailed below. Inclusion
criteria for healthy controls were: ≥16 years, no FD, no
neuropathy, no neuropathic pain or other sources of
pain, normal sural nerve conduction.
The study was approved by the Wurzburg Medical
School Ethics Committee and was conducted in accord-
ance with the Declaration of Helsinki. Written informed
consent was obtained from all study participants.
Clinical examination, questionnaire assessment, and
laboratory tests
All patients underwent thorough neurological examin-
ation and were assessed using pain questionnaires: the
German version of the Neuropathic Pain Symptom Inven-
tory (NPSI) [9,10] and the Graded Chronic Pain Scale
(GCPS), modified to a four-week recall [11]. The NPSI in-
vestigates pain intensity and characteristics resulting in a
sum score between 0 (no pain at all) and 1 (maximum
pain). The 24-hour recall version was used. From the
GCPS we used the total score of the three pain intensity
items as an indicator of pain severity, and the total score
of the three items rating interference with social, occupa-
tional, and recreational activities as a disability score. To
address depressive symptoms we used the German versionof the Center for Epidemiologic Studies Depression Scale
(“Allgemeine Depressionsskala”, ADS) [12]. The ADS
ranges from 0 to 60; a score ≥ 16 is assumed clinically sig-
nificant. The one week recall version was used. To make
the diagnosis of small fiber neuropathy, clinical presen-
tation, QST findings, and intraepidermal nerve fiber den-
sity (IENFD) were assessed according to Lacomis [13]
(methods description see below). Depending on the num-
ber of pathological findings, definite, probable, and pos-
sible small fiber neuropathy was diagnosed. Laboratory
tests included whole blood and differential cell counts;
C-reactive protein; serum electrolytes; renal, liver, and thy-
roid function tests; erythrocyte sedimentation rate. Renal
function was assessed by determining the glomerular fil-
tration rate (GFR). Renal function, as one indicator of
FD severity, was considered normal if GFR ≥ 60 ml/min/
1.73 m2 and reduced if GFR < 60 ml/min/1.73 m2 [14-16].
The right sural nerve was investigated in all study partici-
pants using surface electrodes and following a standard
procedure [17] to exclude large fiber neuropathy. The re-
sults were compared with laboratory normal values: for
antidromic sural nerve sensory nerve action potential
(SNAP) amplitude ≥ 10 μV for age < 65 years, ≥ 5 μV for
age > 65 years; for sural nerve conduction velocity (NCV) >
40 m/s for all ages.
Quantitative sensory testing (QST)
QST was performed using a calibrated device (Somedic,
Hörby, Sweden) and following a standardized procedure
[18]. For individual analysis patients` data were compared
with published reference values [19]. For group analysis
patients` data were compared with values of age- and
gender-matched healthy controls. All subjects were in-
vestigated at the left dorsal foot. Based on the log
transformed raw values for each QST item a z-score sen-
sory profile was calculated as follows: z-score = (value of
the subject – mean value of controls)/standard deviation
of controls. Negative z-scores indicate loss of sensation,
positive z-scores indicate gain of sensation. We deter-
mined cold and heat detection thresholds (CDT, HDT)
and the ability to detect temperature changes (thermal
sensory limen, TSL) as small fiber functions. Paradoxical
heat sensation (PHS) was recorded if the subject experi-
enced cold as heat. We additionally determined the vibra-
tion detection threshold (VDT) as large fiber function.
The control group for QST measurements consisted of 76
age- and gender matched healthy volunteers (45 female,
31 male; median age: 44 years, 16–73). The difference in
age between patients and matched controls was three
years at maximum.
Pain-related evoked potentials (PREP)
PREP were recorded as previously described [20]. PREP
were elicited by consecutive stimulation at the right and
Table 1 Demographic and clinical characteristics of Fabry
patients at baseline
Baseline
FD patients (N) 76
M, F (N) 31, 45
Median age (range) 43 (16–73) years
Patients on ERT N (%)
- M 24/31 (77%)
- F 10/45 (22%)
Median duration of ERT (range) 4.7 (range 0.1-9.3) years
Patients with GFR ≥60 or <60ml/min/1.73 m2 N (%)
- M ≥60 20/31 (65%)
- M <60 11/31 (35%)
- F ≥60 41/45 (91%)
- F <60 4/45 (9%)
Findings in neurological examination N (%)
- normal 44/76 (58%)
- hypoesthesia (thermal or tactile) 17/76 (22%)
- central pattern (e.g. hemiparesis, Babinski
sign, brisk reflexes)
8/76 (11%)
- loss of ankle reflex 4/76 (5%)
- hypo- or anacusis 4/76 (5%)
- tactile hyperesthesia 2/76 (3%)
Abbreviations: ERT enzyme replacement therapy, F female, FD Fabry disease,
GFR glomerular filtration rate, M male, N number.
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phalanx second and third digit), and feet (dorsum)
using superficial planar concentric electrodes (Inomed
Medizintechnik GmbH, Lübeck, Germany) and a stimu-
lator (Digitimer DS7A, Welwyn Garden City, UK). The
potentials were recorded from Cz by a subcutaneously
placed needle electrode referred to linked earlobes (A1 -
A2) of the international 10–20 system using Signal Soft-
ware (Version 2–16; Cambridge Electronic Design, Lt.,
UK). For stimulation 20 triple pulses with an intensity of
two-fold of the individual pain threshold, duration of 0.5
ms, and random inter-stimulus interval of 15 to 17 sec-
onds were applied. The potentials were recorded using
the following setting: gain: x 5000, bandwidth: 1 Hz-1
kHz, sweep length: 400 ms, digitalization sampling rate:
2.5 kHz. The individual pain threshold was determined
by stimulation of the area of interest twice with increas-
ing and decreasing current intensities until the subject
reported a pin-prick sensation. The average value was
calculated as the individual pain threshold. Two sets of
averaged curves (from n = 10 single sweeps each) were
investigated for reproducible N1- (i.e. first negative
peak), P1- (i.e. subsequent positive peak) latencies and
peak-to-peak amplitudes (PPA) using MATLAB soft-
ware (Version 7.7.0.471, The Math Works, Ismaning,
Germany). All records were individually evaluated to
exclude technical or biological artifacts by the same
investigator who was blinded as for the diagnosis: data
were assessed off-line using coded files. The control
group for PREP recordings consisted of 65 healthy con-
trols (41 female, 25 male; median age: 45 years, 21–75).
Subjects with cardiac pacemakers or with seizures in
their medical history were excluded.
Skin biopsies
For assessment of intraepidermal nerve fiber density
(IENFD) 5-mm skin specimens were obtained (punch
device by Stiefel, Offenbach, Germany). Biopsies were
taken from the lower leg (10 cm above the lateral malle-
olus) and from the back (at th5 level). Skin samples were
processed as described previously [21]. They were
immunoreacted with antibodies to protein-gene product
(PGP) 9.5 (Ultraclone, UK, 1:800; primary antibody) with
goat anti-rabbit IgG labelled with cyanine 3.18 fluo-
rescent probe (Amersham, USA, 1:100; Cy3, secondary
antibody), and IENFD were quantified by an observer
blinded to the identity of the specimen following pub-
lished rules [22]. As reference value we took data of a
cohort of normal samples collected in our laboratory:
lower leg: n = 110 (63 females, 47 males), median age: 50
years (range 20–84), median IENFD 7 fibers/mm, range
1–15 fibers/mm; back: n = 42 (23 female, 19 males), me-
dian age: 50, range 20–81, median IENFD 22 fibers/mm,
range 6–40 fibers/mm.Statistical analysis
We used IBM SPSS Statistics Version 20.0 (IBM, Ehningen,
Germany) for statistical analysis and creation of graphs.
Non-normally distributed data were compared with the
non-parametric Mann–Whitney test. Data with normal
distribution were analyzed using one-way ANOVA. Data
distribution was tested with the Kolmogorov-Smirnov-test
and by observing data histograms. Results of non-normally
distributed data are given as median and range and are il-
lustrated as box plots. Results of normally distributed data
are given as mean +/− standard deviation and are illus-
trated as bar graphs. For correlation analyses we used the
bivariate Spearman correlation. P-values < 0.05 were con-
sidered significant.
Results
Clinical data, questionnaire results, and laboratory findings
Table 1 gives baseline data of the patient population.
Neurological examination was normal in 44/76 cases
(58%). The pathological findings mainly in the peripheral
nervous system are summarized in Table 1. Neurophysio-
logical assessment of the sural nerve revealed normal
SNAP and NCV in 71/76 (93%) cases; in four patients a
slight reduction in SNAP and NCV was found and in one
case no potential could be obtained as a sign of sensory




Figure 1 Sensory profile of Fabry patients. The bar graphs show
the z-score sensory profiles of quantitative sensory testing (QST) at the
left dorsal foot in Fabry patients compared to healthy controls. Healthy
controls are represented by the black zero line. Z-scores < 0 display loss
of function, z-scores >0 show gain of function. a) Male Fabry patients
have elevated detection thresholds for cold and warm (CDT, WDT),
while the thermal sensory limen (TSL) for changing temperatures and
the vibration detection threshold (VDT) was not different from controls.
b) Female Fabry patients do not differ from female controls except for
slightly elevated WDT. *p < 0.05, **p < 0.01.
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sence of small fiber neuropathy: 16 patients had definite
(11 men, 5 women), 35 patients had probable (17 men, 18
women), and 25 patients had possible small fiber neur-
opathy (3 men, 22 women). Assessment of pain using the
NPSI did not show any intergroup differences, as almost
all patients reported on “no pain” in the last 24 hours
(data not shown). The GCPS (4-week recall) revealed
higher pain intensities in FD patients (p < 0.001 for both
genders) and higher disability scores due to pain (p < 0.05
for males, p < 0.001 for females) compared to healthy con-
trols (Additional file 1: Figure S1a). Forty-three patients
did not take analgesic medication; 19 patients used anal-
gesic drugs on demand (n = 8: acetaminophen; n = 5: as-
pirin; n = 4: tramadol; n = 1 each: tilidine, ibuprofen,
metamizol); twelve patients were on regular analgesic
medication (n = 4: pregabalin; n = 2: gabapentin; n = 2:
metamizol; n = 1 each: flupirtine, carbamazepine, tilidine,
tramadol). The ADS showed higher scores for male and
female FD patients compared to controls (p < 0.001 each,
Additional file 1: Figure S1b). None of the patients was on
antidepressant therapy. In 15/76 (20%) cases renal func-
tion was impaired; five male patients were on dialysis.
Male FD patients have impaired thermal perception
In line with previous reports [4,5,23] we found elevated
CDT (p < 0.01) and WDT (p < 0.05) in male Fabry patients
compared with male controls (Figure 1a). Female patients
did not differ from female controls (Figure 1b). Male pa-
tients had higher thermal perception thresholds and im-
paired vibration sense compared to female FD patients
(CDT: p < 0.05, WDT: p < 0.001, TSL: p < 0.01, VDT:
p < 0.01). PHS was present in none of the male patients
and in 9/45 (20%) female FD patients. As shown earlier male
patients with impaired renal function (GFR < 60 ml/min/
1.73 m2) had most severe impairment in thermal percep-
tion (Additional file 2: Figure S2). Women with reduced
α-GAL activity did not differ in QST parameters from
women with normal enzyme activity.
Male Fabry patients have reduced PREP amplitudes
PREP data from both sides were pooled, since there was
no difference between the right and left side for any sub-
ject group, investigated area, or PREP parameter. Stimulus
intensities did not differ between groups for all three areas.
PREP N1 and P1 latencies did not differ between FD pa-
tients and controls (Figure 2a-c). Peak-to-peak amplitudes
(PPA), however, were lower in male Fabry patients com-
pared to male controls upon stimulation at face (p < 0.01),
hands (p < 0.05), and feet (p < 0.01, Figure 2d-f). Male
Fabry patients also had lower PPA compared to female pa-
tients (hand: p < 0.05, foot: p < 0.01, Figure 2d-f). When
comparing data of male Fabry patients with GFR < 60 and
GFR > 60 with data of healthy male controls, only patientswith impaired renal function showed reduced PPA after
eliciting PREP from face (p = 0.012), hands (p = 0.007),
and feet (p = 0.007, Figure 3a-c). Stimulus intensities did
not differ between patients and controls at any site.
Women with reduced α-GAL activity did not differ from
women with nor- mal enzyme activity as for PREP param-
eters. Additional file 3: Figure S3 shows an example of a
PREP recording after stimulation at the face.
Male Fabry patients with advanced disease have the most
marked reduction in skin innervation
Twenty male patients (20/31, 65%) and 27/45 female pa-
tients (60%) agreed to skin punch biopsy. In line with pre-
vious findings [5] we found reduced distal and proximal
IENFD in male patients compared to healthy controls.
Fiber reduction was most prominent in male patients with
impaired renal function: distal (p < 0.001) and proximal
(p < 0.05) IENFD was lower compared to male healthy
Figure 2 Pain-related evoked potentials from face, hands, and feet stratified for gender. Pain-related evoked potentials (PREP) in patients
with Fabry disease and in healthy controls. a, b, c: N1 and P1 latencies of Fabry patients are not different from controls after eliciting PREP at the
face, hand, and feet. d, e, f: Peak-to-peak amplitudes (PPA) of PREP are reduced in male Fabry patients when PREP is elicited at the face, the
hands, or the feet. *p < 0.05, **p < 0.01.
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tients with reduced renal function had lower distal IENFD
than female controls (p < 0.05, Additional file 4: Figure
S4a), while skin innervation was not different at the back
(Additional file 4: Figure S4b). Lower GFR correlated
with lower distal IENFD (correlation coefficient: 0.508,
p < 0.001) and with lower proximal IENFD (correlation
coefficient: 0.369, p < 0.05). Women with reduced α-GAL
activity did not differ from women with normal enzyme
activity as for skin innervation.
PREP amplitudes correlate with impaired thermal
perception in Fabry patients
A positive correlation was found between PREP PPA
elicited at the feet and thermal perception thresholds
(CDT, WDT) determined at the feet of Fabry patients(Figure 4a, b). In male patients a positive correlation was
found for CDT (correlation coefficient: 0.564, p < 0.01)
and for WDT (correlation coefficient: 0.390, p < 0.05). In
female patients a positive correlation was found only for
CDT (correlation coefficient: 0.340, p < 0.05). TSL and
VDT did not correlate with PREP PPA in both genders
(Figure 4c, d). Also, distal IENFD did not show a correl-
ation with PREP parameters obtained after stimulation
at the feet (illustrated for PPA in Figure 4e).
Discussion
We prospectively investigated a large cohort of consecu-
tive Fabry patients with small fiber neuropathy using
electrical stimulation of A-delta fibers (PREP), and com-
pared the findings with complementary methods for
small fiber function and morphology, namely QST and
Figure 3 Pain-related evoked potential amplitudes from face,
hands, and feet stratified for gender and disease severity.
Boxplots show the comparison of PREP PPA stratified for renal
function. Male Fabry patients with impaired renal function have
reduced PREP PPA after eliciting PREP from face (p = 0.012, a), hands
(p = 0.007, b), and feet (p = 0.007, c). *p < 0.05, **p < 0.01.
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that A-delta fiber conduction can easily be assessed using
PREP, that A-delta fiber conduction is impaired mainly in
male Fabry patients with advanced disease, and that
pathological PREP parameters correlate with reduced
thermal perception.
Elevated cold detection thresholds are the most
marked clinical finding when examining the peripheral
nervous system in male Fabry patients [2,4,5,23-28]. In-
nocuous cold sensation is mostly an A-delta fiber func-
tion with some C-fiber participation [29]. PREP allows
the activation of A-delta afferents in superficial skin
layers by the high current intensity when applying low
current stimulation. This is achieved by the usage of
concentric electrodes that have a small anode–cathode
distance. The electrical stimulation leads to a pin-prick
sensation, and nerve conduction velocities of fibers stim-
ulated by such concentric electrodes are in range with
those of A-delta fibers [20, 30-32]. Using PREP, we found
a reduction in evoked potential amplitudes in male Fabry
patients which was mostly due to the subgroup with ad-
vanced disease. The finding of reduced PREP amplitudes
is consistent with data from studies investigating pa-
tients with small fiber pathology in diabetes [32], HIV
infection [33], and fibromyalgia syndrome [20]. More-
over, PREP amplitudes positively correlated with cold
and warm perception as measured with QST mainly in
male Fabry patients. This underscores the notion that
small fiber neuropathy in FD leads to A-delta impair-
ment. This finding is also supported by the only previ-
ous neurophysiological study on small fibers in FD,
which used laser evoked potentials (LEP) in seven male
Fabry patients and found lower A-delta LEP amplitudes
compared to controls [34].
The reason for A-delta fiber dysfunction in FD is not
fully understood. One hypothesis is that the peripheral
nerve fibers degenerate due to Gb3 deposits in dorsal
root ganglion (DRG) neurons. Such deposits have been
detected in histopathological studies in Fabry patients
[35]. Accumulation of Gb3 in DRG may lead to neuronal
apoptosis with a dying back neuropathy in terms of a
ganglionopathy and may result in reduced IENFD. This
fits well to the observed general reduction of intraepidermal
nerve fibers in Fabry patients also in skin from the back,
which normally is preserved from intraepidermal fiber loss
in peripheral neuropathies spreading from distal to prox-
imal. The reason why small fibers are more vulnerable is
unknown. Gb3 deposition in neurons of DRG may also
lead to neuronal dysfunction e.g. by altering cellular excit-
ability on the basis of ion channel alterations. This has
been shown for endothelial potassium channels in the
Fabry mouse model [36]. As a consequence sensory im-
pairment with clinically observed thermal hypoesthesia
may occur.
Figure 4 Correlations of sensory profile and nerve fiber density with pain-related evoked potential amplitudes. Scatter plots show
correlations between PREP peak-to-peak-amplitudes (PPA) recoded after stimulation at the feet and QST parameters (warm detection threshold,
WDT; cold detection threshold, CDT; thermal sensory limen, TSL; vibration detection threshold, VDT). a) PREP PPA correlated positively with CDT
in male (correlation coefficient: 0.564, p = 0.002) and female Fabry patients (correlation coefficient: 0.340, p = 0.034). b) PREP PPA correlated
positively with WDT only in male Fabry patients (correlation coefficient: 0.390, p = 0.04). c, d) TSL and VDT did not correlate with PREP PPA in
either gender. e) Distal IEFND did not correlate with PREP PPA obtained after stimulation at the foot.
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sive deterioration in small fiber conduction, function,
and morphology mainly in men with advanced disease
severity is plausible because hemizygote men have a
higher Gb3 load and Gb3 deposition increases with time.
Moreover, Gb3 clearance by ERT in DRG neurons may
be hampered by the blood-brain-barrier possibly re-
sulting in deterioration of cold detection thresholds even
under treatment [5].
One limitation of our study is that we had to recruit in-
dividual control groups for QST, PREP, and skin punch bi-
opsy. The majority of the control subjects refused to takepart in all three study sections (QST for one hour, PREP
for another hour, skin punch biopsy for another 20 mi-
nutes and biopsy at two body sites). However, strict in-
and exclusion criteria were observed and patients and
controls were matched as for gender and age.
Conclusions
Our study gives evidence for A-delta nerve fiber impair-
ment mainly in male Fabry patients with advanced dis-
ease severity and show that PREP measurements are an
easily applicable, robust, and objective method to inves-
tigate A-delta carried sensory pathways.
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Additional file 1: Figure S1. Sensory profile of Fabry patients stratified
for gender and disease severitySensory profile of Fabry patients stratified
for gender and disease severity. The bar graphs show the z-score sensory
profiles of quantitative sensory testing (QST) at the left dorsal foot in
Fabry patients compared to healthy controls after stratification for gender
and renal function. Healthy controls are represented by the black zero
line. Z-scores < 0 display loss of function, z-scores >0 show gain of
function. Male Fabry patients with impaired renal function (i.e. glomerular
filtration rate [GFR] < 60 ml/min/1.73 m2 show most impaired perception
thresholds for cold and warm (CDT, WDT) and temperature changes
(thermal sensory limen [TSL]). Also the vibration detection threshold
(VDT) is impaired. Male patients with normal renal function (GFR ≥ 60 ml/
min/1.73 m2) also show impairment of CDT, WDT, and TSL, however, less
severe than in male patients with impaired renal function. Female
patients with reduced renal function also show a tendency for impaired
CDT and WDT, while women with normal renal function do not differ
from controls.
Additional file 2: Figure S2. Pain and depression questionnaire
resultsPain and depression questionnaire results. Results of questionnaire
assessment with the Graded Chronic Pain Scale (GCPS) and the
depression scale “Allgemeine Depressionsskala” (ADS). A) Male and
female Fabry patients have higher scores for pain intensity and disability
due to pain in the last four weeks compared to healthy controls. B) Fabry
patients reach higher scores for depressive symptoms on the ADS
compared to healthy controls independent of gender. The horizontal line
in the boxplots represent median values; the boxes end with the 25th
and 75th quartile; the whiskers indicate the highest and lowest value.
*p < 0.05, **p < 0.01, ***p < 0.001.
Additional file 3: Figure S3. PREP record after stimulation at the
facePREP record after stimulation at the face. The upper plot shows a
PREP record from Cz after triple electrical stimulation at the face (above
eyebrow). The three parameters investigated were A) the N1 latency, B)
the P1 latency, and C) the peak-to-peak amplitude. The lower plot shows
the control record of possible blink artifacts during the stimulation at the
face, which might disturbe the PREP recordings. The zero line in the
illustrated case shows that no blink artifacts were present.
Additional file 4: Figure S4. Results of intraepidermal nerve fiber
density stratified for gender and disease severityResults of intraepidermal
nerve fiber density stratified for gender and disease severity.
Intraepidermal nerve fiber density (IENFD) at the lower leg (a) and the
back (b) of Fabry patients and of healthy controls assessed with the
pan-axonal marker PGP9.5 and stratified for renal function. a + b) Male
patients with impaired renal function have lower PGP9.5 positive IENFD
compared to healthy controls at the lower leg and the back. Also female
patients with reduced renal function have lower IENFD at the lower leg.
*p < 0.05, **p < 0.01, ***p < 0.001.
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